Bullish Case: Known: CNSP shows mean‑reversion and is bouncing (+11.7% vs 1 month) after a deeper dip (‑13.9% vs 60 days). The CNSP return surface is dominated by negative outcomes but still leaves a thin, non‑zero likelihood of rebounds from those regimes. Inferred: elevated SPY implied vol implies choppy pricing where a credible CNS catalyst (e.g., Berubicin trial/progress news) could trigger a fast re‑rate. Uncertain on timing.

Bearish Case: Known: Helium’s AI forecast is -3.55% and the realized/forecast correlation is slightly negative (-0.3), so bearish drift is plausible but signal weak. The CNSP return surface is heavily concentrated near extreme losses (close to -100%), consistent with a persistent downside regime. Uncertain: SPY’s volatility surface suggests macro uncertainty could amplify small‑cap biotech selloffs. Without a specific, validated clinical/commercial catalyst, dilution/survival risk may dominate.

Potential Outcomes:

1. 45%: No Berubicin/news catalyst into mid‑late July → -10–25% (falsifiable: flat filings/PR + falling volume).
2. 20%: Positive trial/progress headline w/ tangible response/metrics → +30–70% snap (falsifiable: PR + rising OI/volume).
3. 20%: Financing/dilution or adverse safety/efficacy detail → -35–60%.
4. 15%: Mean‑reversion rangebound → 0–15%.

July 11, 2026